Pharmacotherapy of Comorbid Mood, Anxiety, and Substance Use Disorders

References

• Aagaard J., Vestergaard P., Maarbjerg K. Adherence to lithium prophylaxis, II: multivariate analysis of clinical, social, and psychosocial predictors of nonadherence. Pharmacopsychiatry 1988; 21: 166–170, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Albanese M. J., Clodfelter R. C., Khantzian E. J. Divalproex sodium in substance abusers with mood disorder. J. Clin. Psychiatry 2000; 61(12)916–921, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Amit Z., Sutherland E. A., Gill K., Ogren S. O. Zimeldine: a review of its effects on ethanol consumption. Neurosci. Biobehav. Rev. 1984; 8(1)35–54, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Barlow D. H., Lehman C. L. Advances in the psychosocial treatment of anxiety disorders. Implications for national health care. Arch. Gen. Psychiatry 1996; 53(1)727–735, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Bohn M. J., Babor T. F., Kranzler H. R. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J. Stud. Alcohol 1995; 56: 423–432, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bowden C. L. Clinical correlates of therapeutic response in bipolar disorder. J. Affect. Disord. 2001; 67(1–3)257–265, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Brady K. T., Casto S., Lydiard R. B., Malcolm R., Arana G. Substance abuse in an inpatient psychiatric sample. Am. J. Drug Alcohol Abuse 1991; 17(4)389–397, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Brady K. T., Dansky B. S., Back S. E., Foa E. B., Carroll K. M. Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: preliminary findings. J. Subst. Abuse Treat. 2001; 21(1)47–54, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Brady K. T., Sonne S. C., Anton R., Ballenger J. C. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J. Clin. Psychiatry 1995; 56(3)118–121, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Brady K. T., Sonne S. C., Malcolm R. J., Randall C. L., Dansky B. S., Simpson K., Roberts J. S., Brondino M. Carbamazepine in the treatment of cocaine dependence: subtyping by affective disorder. Exp. Clin. Psychopharmacol. 2002; 10(3)276–285, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Brady K. T., Sonne S., Killeen T., Simpson K. N., Randall C., Back S. E., Anton R. F. (2003) Sertraline in comorbid PTSD/alcohol dependence. Poster Abstracts of Papers, 26th Annual Scientific Meeting of the Research Society on Alcoholism, Ft. Lauderdale, FL, June, 21–252003, I. Diamond. Lippincott, Williams & Wilkins, Baltimore, MD, 45: 146A
   Google Scholar
• Bristol-Myers Squibb Company. Nefazodone hydrochloride (Serzone) Prescribing Information
   Google Scholar
• Brown E. S., Nejtek V. A., Perantie D. C., Orsulak P. J., Bobadilla L. Lamotrigine in patients with bipolar disorder and cocaine dependence. J. Clin. Psychiatry 2003; 64(2)197–201, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Brown M. E., Anton R. F., Malcolm R., Ballenger J. C. Alcoholic detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol. Psychiatry 1986; 43(1)107–113
   Google Scholar
• Brown R. A., Evans M., Miller I. W., Burgess E. S., Mueller T. I. Cognitive-behavioral treatment for depression in alcoholism. J. of Consult. and Clin. Psychol. 1997; 65(5)715–726, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chambless D. L., Cherney J., Caputo G. C. Anxiety disorders and alcoholism: a study with inpatient alcoholics. J. Anxiety Disord. 1987; 18(1)29–40, [CROSSREF]
   Google Scholar
• Chengappa K. N., Kambhampati R. K., Perkins K., Nigam R., Anderson T., Brar J. S., Vemulapalli H. K., Atzert R., Key P., Kang J. S., Levine J. Bupropion sustained-release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychiatry 2001; 62(7)503–508, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Cocco K. M., Carey K. B. Psychometric properties of the Drug Abuse Screening Test in psychiatric outpatients. Psychol. Assess. 1998; 10: 408–414, [CROSSREF]
   Web of Science ®Google Scholar
• Cornelius J. R., Bukstein O. G., Birmaher B., Salloum I. M., Lynch K., Pollock N. K., Gershon S., Clark D. Fluoxetine in adolescents with major depression and an alcohol use disorder: an open-label trial. Addict. Behav. 2001; 26(5)735–739, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cornelius J. R., Bukstein O. G., Birmaher B., Salloum I. M., Kelly T. M., Walters M. C., Wood D. S., Clark D. B. (2003) Fluoxetine in depressed AUD adolescents: a three-year follow-up evaluation. Poster Abstracts of Papers, 26th Annual Scientific Meeting of the Research Society on Alcoholism, Ft. Lauderdale, FL, June, 21–252003, I. Diamond. Lippincott, Williams & Wilkins, Baltimore, MD, 839: 145A
   Google Scholar
• Cornelius J. R., Salloum I. M., Ehler J. G., Jarrett P. J., Cornelius M. D., Perel J. M., Thase M. E., Black A. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 1997; 54(1)700–705, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Cornelius J. R., Salloum I. M., Thase M. E., Haskett R. F., Daley D. C., Jones-Barlock A., Upsher C., Perel J. M. Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacol. Bull. 1998; 34(1)117–121, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Cottler L., Compton W., Mager D., Spitznagel E., Janca A. Posttraumatic stress disorder among substance users from the general population. Am. J. Psychiatry 1992; 149(1)664–670, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Covey L. S., Glassman A. H., Stetner F., Rivelli S., Stage K. A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Am. J. Psychiatry 2002; 159(10)1731–1737, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Crum R. M., Anthony J. C. Cocaine use and other suspected risk factors for obsessive compulsive disorder: a prospective study with data from the Epidemiologic Catchment Area surveys. Drug Alcohol Depend. 1993; 31: 281–295, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dalack G. W., Glassman A. H., Rivelli S., Covey L., Stetner F. Mood, major depression, and fluoxetine response in cigarette smokers. Am. J. Psychiatry 1995; 152(1)398–403, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Danion J. Ml., Neunreuther C., Krieger-Finance F., Imbs J. L., Singer L. Compliance with long-term lithium treatment in major affective disorders. Pharmacopsychiatry 1987; 20(1)230–231, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Davidson J. Drug therapy of post-traumatic stress disorder. Br. J. Psychiatry 1992; 160(1)309–314, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Davidson J. R., Rothbaum B. O., van der Kolk B. A., Sikes C. R., Farfel G. M. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch. Gen. Psychiatry 2001; 58: 485–492, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Deas D., Randall C. L., Roberts J. S., Anton R. F. A double-blind, placebo-controlled trial of sertraline in depressed adolescent alcoholics: a pilot study. Hum. Psychopharmacol. 2000; 15(6)461–469, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Dundon W., Lynch K., Pettinati H. M., Lipkin C., Briancesco L. (2003) Six-month follow-up of sertraline pharmacotherapy in type A and type B alcohol dependence. Abstracts of Papers, 26th Annual Scientific Meeting of the Research Society on Alcoholism, Ft. Lauderdale, FL, June, 21–252003, I. Diamond. Lippincott, Williams & Wilkins, Baltimore, MD, 858: 148A
   Google Scholar
• Franken I. H., Hendriks V. M. Screening and diagnosis of anxiety and mood disorders in substance abuse patients. Am. J. Addict. 2001; 10: 30–39, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Geller B., Cooper T. B., Sun K., Zimerman B., Frazier J., Williams M., Heath J. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J. Am. Acad. Child Adolesc. Psychiatry 1998; 37(2)171–178, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gill K., Amit Z., Koe B. K. Treatment with sertraline, a new serotonin uptake inhibitor, reduces voluntary ethanol consumption in rats. Alcohol 1988; 5(5)349–354, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Gill K., Amit Z., Ogren S. O. The effects of zimeldine on voluntary ethanol consumption: studies on the mechanism of action. Alcohol 1985; 2(2)343–347, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Goldberg J. F., Whiteside J. E. The association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study. J. Clin. Psychiatry 2002; 63(9)791–795, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• all S. M., Reus V. I., Munoz R. F., Sees K. L., Humfleet G., Hartz D. T., Frederick S., Triffleman E. Nortriptyline and cognitive-behavioral therapy in the treatment of smoking cessation. Arch. Gen. Psychiatry 1998; 55(8)683–690, [CROSSREF]
   PubMedGoogle Scholar
• Hamilton S. P., Klimchak C., Nunes E. V. Treatment of depressed methadone maintenance patients with nefazodone: a case series. Am. J. Addict. 1998; 7(4)309–312, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Hasin D. S., Trautman K. D., Miele G. M., Samet S., Smith M., Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am. J. Psychiatry 1996; 153(1)1195–1201, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Hernandez-Avila C. A., Modesto V., Feinn R., Kranzler H. R. (2003) A double-blind, placebo-controlled trial of nefazodone in patients with comorbid alcohol dependence and major depression. Abstracts of Papers, 26th Annual Scientific Meeting of the Research Society on Alcoholism, Ft. Lauderdale, FL, June, 21–252003, I Diamond. Lippincott, Williams, & Wilkins, Baltimore, MD, 841: 146A
   Google Scholar
• Hitsman B., Pingitore R., Spring B., Mahableshwarkar A., Mizes J. S., Segraves K. A., Kristeller J. L., Xu W. Antidepressant pharmacotherapy helps some cigarette smokers more than others. J. Consult. Clin. Psychol. 1999; 67(4)547–554, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Hurt R. D., Sachs D. P., Glover E. D., Offord K. P., Johnston J. A., Dale L. C., Khayrallah M. A., Schroeder D. R., Glover P. N., Sullivan C. R., Croghan I. T., Sullivan P. M. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 1997; 337(17)1195–1202, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Jacobsen L. K., Southwick S. M., Kosten T. R. Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am. J. Psychiatry 2001; 158(1)1184–1190, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Jorenby D. E., Leischow S. J., Nides M. A., Rennard S. I., Johnston J. A., Hughes A. R., Smith S. S., Muramoto M. L., Daughton D. M., Doan K., Fiore M. C., Baker T. B. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 1999; 340(9)685–691, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Keck P. E., McElroy S. L., Strakowski S. M., Stanton S. P., Kizer D. L., Balistreri T. M., Bennett J. A., Tugrul K. C., West S. A. Factors associated with pharmacologic noncompliance in patients with mania. J. Clin. Psychiatry 1996; 57(7)292–297, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Keller M. B., Lavori P. W., Coryell W., Andreasen N. C., Endicott J., Clayton P. J., Klerman G. L., Hirschfeld R. M. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. JAMA 1986; 255(22)3138–3142, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Kessler R. C., McGonagle K. A., Zhao S., Nelson C. B., Hughes M., Eshleman S., Wittchen H. U., Kendler K. S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry 1994; 51(1)8–19, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kessler R. C., Sonnega A., Bromet E., Hughes M., Nelson C. B. Posttraumatic stress disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry 1995; 52(12)1048–1060, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kessler R. C., Nelson C. B., McGonagle K. A., Edlund M. J., Frank R. G., Leaf P. J. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am. J. Orthopsychiatry 1996; 66(1)17–31, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kranzler H. R., Burleson J. A., Del Boca F. K., Babor T. F., Korner P., Brown J., Bohn M. J. Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch. Gen. Psychiatry 1994; 51: 720–731, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kranzler H. R., Kadden R. M., Babor T. F., Tennen H., Rounsaville B. J. Validity of the SCID in substance abuse patients. Addiction 1996; 91: 859–868, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Krupitsky E. M., Rudenko A. A., Burakov A. M., Zvartau E. E., Slavina T. Y., Grinenko A. Y., Krystal J. H. (2003) Anti-glutamate treatments for alcohol detoxification: a double-blind, placebo-controlled pilot study of lamotrigine and memantine. Abstracts of Papers, 26th Annual Scientific Meeting of the Research Society on Alcoholism, Ft. Lauderdale, FL, June, 21–252003, I Diamond. Lippincott, Williams & Wilkins, Baltimore, MD, 860: 149A
   Google Scholar
• Kushner M. G., Sher K. J., Beitman B. D. The relation between alcohol problems and the anxiety disorders. Am. J. Psychiatry 1990; 147(1)685–695, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Lima M. S., Reisser A. A., Soares B. G., Farrell M. Antidepressants for cocaine dependence. Cochrane Database Syst. Rev. 2003; 4(1)2950
   Google Scholar
• Louie A. K., Lannon R. A., Ketter T. A. Treatment of cocaine-induced panic disorder. Am. J. Psychiatry 1989; 146(1)40–44, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Lydiard R. B., Brawman-Mintzer O., Ballenger J. C. Recent developments in the psychopharmacology of anxiety disorders. J. Consult. Clin. Psychol. 1996; 6(1)660–668
   Google Scholar
• Lydiard R. B., Falsetti S. A. Treatment options for social phobia. Psychiatr. Ann. 1995; 25(1)570–576
   Google Scholar
• Malcolm R., Anton R. F., Randall C. L., Johnston A., Brady K., Thevos A. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin. Exp. Res. 1992; 16: 1007–1013, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Malcolm R., Myrick H., Roberts J., Wang W., Anton R., Ballenger J. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J. Gen. Internal Med. 2002; 17(1)1–7, [CROSSREF]
   PubMedGoogle Scholar
• Margolin A., Kosten T. R., Avants S. K., Wilkins J., Ling W., Beckson M., Arndt I. O., Cornish J., Ascher J. A., Li S. L., Bridge P. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend. 1995; 40(1)125–131, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Marshall J. R. The diagnosis and treatment of social phobia and alcohol abuse. Bull. Menninger Clin. 1994; 58(1)58–66
   Google Scholar
• Marshall R. D., Beebe K. L., Oldham M., Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am. J. Psychiatry 2001; 158: 1982–1988, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mason B. J., Kocsis J. H., Ritvo E. C., Cutler R. B. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996; 275(10)761–767, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Massion A. O., Warshaw M. G., Keller M. B. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am. J. Psychiatry 1993; 150(1)600–607, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Matching Alcoholism Treatments to Client Heterogeneity. Project MATCH posttreatment drinking outcomes. J. Stud. Alcohol 1997; 58(1)7–29
   PubMedGoogle Scholar
• McDowell D. M., Levin F. R., Seracini A. M., Nunes E. V. Venlafaxine treatment of cocaine abusers with depressive disorders. Am. J. Drug Alcohol Abuse 2000; 26(1)25–31, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McGrath P. J., Nunes E. V., Stewart J. W., Goldman D., Agosti V., Ocepek-Welikson K., Quitkin F. M. Imipramine treatment of alcoholics with primary depression. Arch. Gen. Psychiatry 1996; 53(1)232–240, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• McRae A. L., Sonne S. C., Brady K. T. The use of buspirone for the treatment of persistent anxiety in methadone-maintained patients. Am. J. Addictions. 2004; 13(1)53–63, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Milby J. B., Sims M. K., Khuder S., Schumacher J. E., Huggins N., McLellan A. T., Woody G., Haas N. Psychiatric comorbidity: prevalence in methadone maintenance treatment. Am. J. Drug Alcohol Abuse 1996; 22(1)95–107, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Myrick D. H., Brady K. T. Social phobia in cocaine-dependent individuals. Am. J. Addict. 1996; 6(1)99–104
   Google Scholar
• Naranjo C. A., Knoke D. M. The role of selective serotonin reuptake inhibitors in reducing alcohol consumption. J. Clin. Psychiatry 2001; 62: 18–25, Suppl 20[PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Nunes E. V., Quitkin F. M., Donovan S. J., Deliyannides D., Ocepek-Welikson K., Koenig T., Brady R., McGrath P. J., Woody G. Imipramine treatment of opiate-dependent patients with depressive disorders. Arch. Gen. Psychiatry 1998; 55(1)153–160, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Pande A. C., Davidson J. R., Jefferson J. W., Janney C. A., Katzelnick D. J., Weisler R. H., Greist J. H., Sutherland S. M. Treatment of social phobia with gabapentin: a placebo-controlled study. J. Clin. Psychopharmacol. 1999; 19: 341–348, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Petrakis I., Carroll K. M., Nich C., Gordon L., Kosten T., Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opiate addicts. Drug Alcohol Depend. 1998; 50(1)221–226, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Pettinati H. M., Volpicelli J. R., Kranzler H. R., Luck G., Rukstalis M. R., Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin. Exp. Res. 2000; 24(7)1041–1049, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pettinati H. M., Volpicelli J. R., Luck G., Kranzler H. R., Rukstalis M. R., Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. J. Clin. Psychopharmacol. 2001; 21(2)143–153, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Post R. M. Cocaine psychoses: a continuum model. Am. J. Psychiatry 1975; 132(1)225–231, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Post R. M., Weiss S. R. Psychomotor stimulant vs local anesthetic effects of cocaine: role of behavioral sensitization and kindling. Natl. Inst. Drug Abuse Res. Monogr. Ser. 1988; 88(1)217–238
   Google Scholar
• Post R., Rubinow D., Ballenger J. Conditioning, sensitization and kindling: implications for the course of affective illness. Neurobiology of Mood Disorders, R. M. Post, J. C. Ballenger. Williams & Wilkins, Baltimore, MD 1984; 432–466
   Google Scholar
• Posternak M. A., Mueller T. I. Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence. Am. J. Addict. 2001; 10(1)48–68, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Randall C. L., Johnson M. R., Thevos A. K., Sonne S. C., Thomas S. E., Willard S. L., Brady K. T., Davidson J. R. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress. Anxiety. 2001; 14: 255–462, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Reich L. H., Davies R. K., Himmelhoch J. M. Excessive alcohol use in manic-depressive illness. Am. J. Psychiatry 1974; 131(1)83–86, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Reiger D. A., Farmer M. E., Rae D. S., Locke B. Z., Keith S. J., Judd L. J., Goodwin F. K. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990; 264(1)2511–2518, [CROSSREF]
   PubMedGoogle Scholar
• Riggs P. D., Mikulich S. K., Coffman L. M., Crowley T. J. Fluoxetine in drug-dependence delinquents with major depression: an open trial. J. Child. Adolesc. Psychopharmacol. 1997; 7(2)87–95, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Rosen M. I., Kosten T. Cocaine-associated panic attacks in methadone-maintained patients. Am. J. Drug Alcohol Abuse 1992; 18(1)57–62, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Rounsaville B. J., Anton S. F., Carroll K., Budde D., Prusoff B. A., Gawin F. Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch. Gen. Psychiatry 1991; 48(1)43–51, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Roy-Byrne P. P., Pages K. P., Russo J. E., Jaffe C., Blume A. W., Kingsley E., Cowley D. S., Ries R. K. Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2000; 20(2)129–136, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Salloum I. M., Cornelius J. R., Chakravorthy S. (2003) Utility of combined naltrexone valproate treatment in bipolar alcoholics: a randomized, open-label, pilot study. Abstracts of Papers. 26th Annual Scientific Meeting of the Research Society on Alcoholism, Ft. Lauderdale, FL, June, 21–252003, I. Diamond. Lippincott, Williams & Wilkins, Baltimore, MD, 843: 146A
   Google Scholar
• Salloum I. M., Cornelius J. R., Daley D. C., Kirisci L. (2003) Tolerability and safety of valproate in bipolar alcoholics: results from a double blind placebo controlled study. Abstracts of Papers, 26th Annual Scientific Meeting of the Research Society on Alcoholism, Ft. Lauderdale, FL, June, 21–252003, I. Diamond. Lippincott, Williams & Wilkins, Baltimore, MD, 844: 146A
   Google Scholar
• Sattar S. P., Grant K., Bhatia S., Petty F. Potential use of olanzapine in treatment of substance dependence disorders. J. Clin. Psychopharmacol. 2003; 23(4)413–414, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schmitz J. M., Averill P., Stotts A. L., Moeller F. G., Rhoades H. M., Grabowski J. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend. 2001; 63(1)207–214, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Sher L. The role of the endogenous opioid system in the pathogenesis of anxiety disorders. Med. Hypotheses 1998; 50: 473–474, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Shiffman S., Johnston J. A., Khayrallah M., Elash C. A., Gwaltney C. J., Paty J. A., Gnys M., Evoniuk G., DeVeaugh-Geiss J. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl.) 2000; 148(1)33–40, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Smith S. S., Jorenby D. E., Leischow S. J., Nides M. A., Rennard S. I., Johnston J., Jamerson B., Fiore M. C., Baker T. B. Targeting smokers at increased risk for relapse: treating women and those with a history of depression. Nicotine Tob. Res. 2003; 5(1)99–109, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Sonne S. C., Brady K. T. Valproate for alcoholics with bipolar disorder. Am. J. Psychiatry 1999; 156(7)1122, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sonne S. C., Brady K. T., Morton W. A. Substance abuse and bipolar affective disorder. J. Nerv. Ment. Dis. 1994; 182(6)349–352, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Spitzer R. L., Kroenke K., Williams J. B. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders patient Health Questionnaire. JAMA 1999; 282(1)1737–1744, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Strakowski S. M., Sax K. W., McElroy S. L., Keck P. E., Hawkins J. M., West S. A. Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. J. Clin. Psychiatry 1998; 59(9)465–471, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sullivan M. A., Covey L. S. Nicotine dependence: the role for antidepressants and anxiolytics. Curr. Opin. Investig. Drugs 2002; 3(2)262–271, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Weiss F., Ciccocioppo R., Parsons L. H., Katner S., Liu X., Zorrilla E. P., Valdez G. R., Ben-Shahar O., Angeletti S. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. An. N Y Acad. Sci. 2001; 937: 1–26
   PubMed Web of Science ®Google Scholar
• Weiss R. D., Mirin S. M. Tricyclic antidepressants in the treatment of alcoholism and drug abuse. J. Clin. Psychiatry 1989; 50(1)4–11, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Woody G. E., O'Brien C. P., Rickels K. Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone. Am. J. Psychiatry 1975; 132(4)447–450, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Zung W. W., Brodie H. K., Fabre L., McLendon D., Garver D. Comparative efficacy and safety of bupropion and placebo in the treatment of depression. Psychopharmacology (Berl.) 1983; 79(4)343–347, [CROSSREF]
   PubMedGoogle Scholar